沙特阿拉伯王国政府所属的官方政府网站。
周四 25 6月 2026
沙特官方政府网站的域名以下列后缀结尾 gov.sa
沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。
政府网站使用以下协议。 HTTPS 用于加密和安全。
沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。
| المنتج | التاريخ | معلومات السلامة | المرفقات |
|---|---|---|---|
| Gilenya® - Fingolimod | Hemophagocytic syndrome (HPS) reported in patients treated with Gilenya®. |
||
| Neupogen® - Filgrastim | Risk of capillary leak syndrome in patients with cancer. |
||
| ZOFRAN® - Ondansetron | Updated information on posology for intravenous use and dose dependant QT interval prolongation. |
||
| Diane-35® - Ethinylestradiol/Cyproterne | Risk of Thromboembolism. |
||
| MabThera® - Rituximab | The management of hepatitis B reactivation in patients treated with MabThera®. CLICK HERE |
||
| LARIAM® - Mefloquine | Important Safety Update of Prescribing Information for LARIAM®. |
||
| Fenatnyl‐Janssen ® - Fentanyl | Fenatnyl‐Janssen Introduction of New Warning ‐ Serontonin syndrome may occur under co‐administration with serotonergic drugs. |
||
| DUROGESIC® -Fentanyl | Introduction of New Warning-Serontonin syndrome may occur under co-administration with serotonergic drugs. |
||
| VOTRIENT® - Pazopanib | Important change to frequency of Serum liver test monitoring for hepatotoxicity. |
||
| TASIGNA® - Nilotinib | Updated information regarding the possible risk of developing atherosclerosis-related diseases with the use of TASIGNA®. |
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。